Piloty’s acid derivative with improved nitroxyl-releasing characteristics
摘要:
Recent studies have shown that nitroxyl (HNO) ((HNO)-H-1/(NO)-N-3 ), which is the one-electron-reduced form of nitric oxide (NO), has unique biological activities, especially in the cardiovascular system, and HNO-releasing agents may have therapeutic potential. Since few HNO donors are available for use under physiological conditions, we synthesized and evaluated a series of Piloty's acid (PA) derivatives and evaluated their HNO-releasing activity under physiological conditions. N-Hydroxy-2-nitrobenzenesulfonamide (17) was the most efficient HNO donor among our synthesized PA derivatives, including the lead compound, 2-bromo-N-hydroxybenzenesulfonamide (2). The high HNO-releasing activity is suggested to be due to electronic and steric effects. Compound 17 may be a useful tool for biological experiments. (C) 2013 Elsevier Ltd. All rights reserved.
N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
申请人:Johns Hopkins University School of Medicine
公开号:EP2489350A1
公开(公告)日:2012-08-22
The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS
申请人:Johns Hopkins University School of Medicine
公开号:EP1998761A1
公开(公告)日:2008-12-10
NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION
申请人:Cardioxyl Pharmaceuticals, Inc.
公开号:EP2504003B1
公开(公告)日:2016-11-09
Thiol-Sensitive Positive Inotropes
申请人:Paolocci Nazareno
公开号:US20090298795A1
公开(公告)日:2009-12-03
The present invention relates to methods for treating diastolic dysfunction or a disease, disorder or condition associated with diastolic dysfunction, methods for treating heart failure, methods for modulating SR Ca2+ release and/or uptake, methods for enhancing myocyte relaxation, preload or E2P hydrolysis, and methods for treating ventricular hypertrophy.